Pharma's Market
SPECIAL REPORT
MOST SHARED
- Carl Icahn Increases Stake in Chesapeake, Demands Board Seats
- Citigroup Lost $20 Million on Facebook IPO Trades
- Europe Has Wall Street's Bull on a Short Leash
- Romney Leads Poll Of Small Business Owners
- Marc Faber: 100% Chance of Global Recession
- Astronauts Snare SpaceX Rocket
- The Key to a Successful Turnaround
- Judge Says Skilling Can Seek New Trial
- Facebook: The Song — Yes, We're Serious
- Bacon Tourism: From the Davos of Bacon to Bacon Mecca
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- Sticker Shock: What College Is Likely to Cost in 18 Years
- Marc Faber: Chance of Global Recession Is Now 100%
- Icahn Raises Stake in Chesapeake, Wants Board Seats
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- What Happened to Stocks? Most Unloved in 50 Years
- Cool Jobs: From Gold Stacker to Bed Tester
- Many Greeks Moved Their Money Abroad Long Ago
- China, US, Japan Also Have Work to Do: EU's Barroso
RSS FEED
DNDN's Provenge And GSK's Avandia: In FDA Spotlight
Text Size 
Reporter
As a big FDA Advisory Committee meeting is taking place here in Gaithersburg, Maryland on the safety of GlaxoSmithKline's [GSK
Loading...
()
] Avandia, the head of the agency has been named in a separate lawsuit. A non-profit group calling itself "CareToLive" is suing FDA Commissioner Dr. Andrew von Eschenbach over the recent delay in the potential approval of Dendreon's [DNDN
Loading...
()
] Provenge.
An FDA spokesperson says the agency doesn't comment on pending litigation.
The lawsuit accuses the Commish of "arbitrarily and capriciously" denying immediate approval of Provenge and putting the lives of tens of thousands at stake.
The plaintiffs want a federal judge in Ohio where the case was filed to order the drug be made available right away. The suit also names Health and Human Services Secretary Mike Leavitt, another FDA staffer, as well as a controversial doctor who was on the outside panel that reviewed Provenge.
CareToLive calls this action unprecedented. What else would you expect from the most hotly-debated, dramatic drug approval pathways I've ever seen?
Avandia Update
Meantime here at the Gaithersburg Holiday Inn so far team Glaxo has briefed the Advisory Committee. Over and over and over again the company reps said the data are inconclusive and inconsistent and that the drug doesn't have an increased risk of heart attacks.
The FDA is up next. And then later today the panel will vote on the cardiovascular risk and whether it warrants Avandia being pulled from the market. Stay tuned.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
